Clinical Trial Update: Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated bioequivalence between two inhalation formulations containing budesonide 200 µg; the trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergy

Drugs mentioned

• Budesonide Inhalation Formulation A (200 µg) (budesonide)
• Budesonide Inhalation Formulation B (200 µg) (budesonide)

Snippet

Sponsor: Reig Jofre Group | Conditions: Allergy | Phase 1 | Status: COMPLETED